NCT02943720

ATIBAR - Efficacy and Safety of Two Doses of AllerT in Patients Allergic to Birch Pollen

A Multicentre, Double-blind, Placebo-Controlled, Randomized Trial to Assess the Efficacy and Tolerability of Two Dosing Regimens of AllerT in Adults With Birch Pollen Allergic Rhinitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 421 (actual)
• Sponsor: Anergis · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

A multicentre, Double-blind, Placebo-Controlled, Randomized Trial to Assess the Efficacy and Tolerability of Two Dosing Regimens of AllerT, a Combination of Contiguous Overlapping Peptides Derived from Bet v 1, in Adults with Birch Pollen Allergic Rhinitis/Rhinoconjunctivitis

Conditions

• Allergic Rhinitis

Interventions

Type	Name	Description
DRUG	AllerT	Bet v 1 contiguous overlapping peptides mixed with aluminium hydroxide solution
DRUG	placebo	placebo

Timeline

• Start date: 2016-09-01
• Primary completion: 2017-07-01
• Completion: 2017-10-01
• First posted: 2016-10-25
• Last updated: 2018-01-10

Locations

36 sites across 8 countries: Denmark, Finland, Germany, Lithuania, Norway, Poland, Slovakia, Sweden